Test Price
2,800 AEDโ Home Collection Available
NEXMIF Gene Genetic Test (X-linked Intellectual Disability, Non-Syndromic) โ 2,800 AED
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The NEXMIF gene test employs Next-Generation Sequencing (NGS) to detect pathogenic variants linked to X-linked non-syndromic intellectual disability, offering definitive molecular diagnosis for affected males and carrier females. The analysis covers the entire coding region and flanking intronic boundaries, enabling confirmation of a molecular aetiology in individuals with developmental delay or cognitive impairment without syndromic features. It also supports carrier testing in female relatives and prenatal counselling.
| Parameter | Our NEXMIF NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Technology | Next-Generation Sequencing (NGS) | Sanger (single-region analysis) |
| Variant Detection | SNVs, indels, exon-level CNVs | SNVs and small indels only; limited CNV detection |
| Turnaround Time | 3โ4 weeks | 4โ6 weeks |
| Diagnostic Sensitivity | >99.9% for covered alterations | ~95% for point mutations |
| Price (AED) | 2,800 | Variable (typically higher) |
Physician Insight & Safety Protocols
โWhen a child presents with unexplained developmental delay, securing a precise genetic diagnosis offers families much-needed clarity and direction. This NEXMIF NGS test must be discussed in a multidisciplinary setting, and any treatment decisions should be guided by a paediatric neurologist or clinical geneticist. Please remember that test results alone do not replace clinical judgment.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Important Advisory
Do not discontinue any prescribed medication without consulting your doctor.
Exclusion Criteria & Emergency Red Flags
- Inability to obtain valid informed consent (for minors, guardian consent mandatory per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Acute febrile illness or haemodynamic instability at the time of blood collection.
- Known severe coagulopathy not managed by a physician; home collection may be postponed.
- Seek immediate medical attention if the patient develops new-onset seizures, altered consciousness, sudden behavioural regression, or signs of metabolic crisis.
Patient FAQ & Clinical Guidance
1. What is the purpose of the NEXMIF gene test?
A: The NEXMIF gene NGS test identifies disease-causing mutations linked to X-linked non-syndromic intellectual disability, allowing precise diagnosis. This analysis covers the entire coding region and flanking intronic boundaries, enabling confirmation of a molecular aetiology in individuals with developmental delay or cognitive impairment without syndromic features. It also supports carrier testing in female relatives and prenatal counselling.
2. How is the sample collected and does it require special preparation?
A: No fasting needed; a blood sample is collected by our DHA-licensed phlebotomist at your residence between 8 AM and 11 PM using an ISO-certified cold-chain transport system. You need not withhold food or adjust current medications. However, a pre-test genetic counselling session is required to review family history and draw a pedigree chart, ensuring proper consent and result interpretation.
3. What do I do after receiving the results?
A: All reports are reviewed by a DHA-certified consultant clinical geneticist who will schedule a tele-consultation to explain the findings. If a clinically significant variant is identified, genetic counselling for extended family members and cascade testing are coordinated through our clinical team. Continuous follow-up and management plans are aligned with your primary care physician.
UAE Regulatory & Data Privacy Adherence
This test is performed under the regulatory oversight of the Dubai Health Authority (DHA Facility License No. 1143) and adheres to:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability
- ISO 9001:2015 Quality Management System (Cert: INT/EGQ/2509DA/3139)
Clinical & Logistical Metadata
| Test Name | NEXMIF Gene Genetic Test (X-linked Intellectual Disability, Non-Syndromic) |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 weeks |
| Sample Type / Matrix | Peripheral whole blood (3โ5 ml in EDTA tube) or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) โ whole gene sequencing with CNV analysis |
| ICD-10-CM Code | F70.9 |
| LOINC Code | 94051-0 |
| DHA Facility License & Laboratory Address Invariants | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DHA License: 1143 |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians